OX

Oxford Biomedica PLCMUN Oxford Biomedica Stock Report

Last reporting period 30 Jun, 2024

Updated —

Last price

Market cap $B

0.506

Micro

Exchange

XMUN - Boerse Muenchen

OXOA.MU Stock Analysis

OX

Uncovered

Oxford Biomedica PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-49/100

Low score

Market cap $B

0.506

Dividend yield

Shares outstanding

96.283 B

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire and currently employs 959 full-time employees. The firm and its subsidiaries are engaged in viral vector delivery systems, including those based on lentivirus, adeno-associated virus (AAV) and adenovirus. The company provides solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. The firm has built a LentiVector platform, which is focused on a lentiviral vector delivery system. The firm is engaged in working on programs from the pre-clinical to commercial stages across a range of therapeutic areas with global partners. The firm has manufacturing, laboratory and office space across six facilities in Oxford, United Kingdom. The Company’s subsidiary, Oxford Biomedica Solutions LLC, has an AAV manufacturing facility near Boston, Massachusetts, the United States.

View Section: Eyestock Rating